Mayo Clinic | Strategic Alliance Partners

April 15, 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, describes three phase II and phase III trials in myelofibrosis.

March 25, 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the long-term experience from the COMFORT-I and COMFORT-II trials in myelofibrosis.

March 11, 2013

Working in the laboratory and the clinic, Shaji K. Kumar, MD, has made a discovery: that there aren't enough hours in a day.

March 07, 2013

Shaji K. Kumar, MD, is working to understand the genomic intricacies of multiple myeloma, particularly the role played by activity associated with the TP53 gene.

February 28, 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the use of JAK2 inhibitors in patients with myelofibrosis.

February 22, 2013

Axel Grothey, MD, from the Mayo Clinic in Rochester, Minnesota, discusses the effectiveness of bevacizumab beyond disease progression in metastatic colorectal cancer.

February 21, 2013

Genetic or drug-induced alterations of the enzyme CYP2D6 that result in reduced metabolism of tamoxifen are associated with a higher risk of recurrence and death in women with ER–positive breast cancer who receive the drug.

February 13, 2013

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, discusses the antibody-drug conjugate T-DM1 that is being investigated as a treatment for patients with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

February 07, 2013

Axel Grothey, MD, from the Mayo Clinic, Rochester, Minnesota, discusses a survey that examined the perceived benefits and use of adjuvant oxaliplatin in colon cancer.

February 01, 2013

Discussion with Edith Perez, MD, about key research presented at SABCS, ongoing developments in breast cancer treatment, and the current focal areas of her research.

January 30, 2013

The oral diabetic medication metformin may help improve survival in patients with ovarian cancer, according to the results of a retrospective case-control study.

November 06, 2012

Aleksandar Sekulic, MD, PhD, from the Mayo Clinic, Scottsdale, AZ, discusses the administration of vismodegib for the treatment and prevention of basal-cell carcinoma in patients with basal-cell nevus syndrome.

August 30, 2012

Dr. Aleksandar Sekulic, from the Mayo Clinic in Arizona, on the Hedgehog Pathway Inhibitor Vismodegib for Basal Cell Carcinoma.

July 11, 2012

Marital status is an independent predictor of disease-related mortality and overall mortality in men with prostate cancer.

May 11, 2012

Dr. Stephen Ansell, from the Mayo Clinic, on Treating Patients With Waldenström Macroglobulinemia

April 24, 2012

Cutaneous melanoma is becoming increasingly common in young adults, with an 8-fold increase among young adult females and a 4-fold increase among young adult males.

April 23, 2012

Dr. Edith Perez, from the Mayo Clinic, Describes the Breast Cancer Translational Genomics Program

April 09, 2012

Dr. Ruben Mesa, from Mayo Clinic, Arizona, Discusses the COMFORT Ruxolitinib Trials

April 03, 2012

Adjuvant chemotherapy improves disease-free and overall survival in many--but not all--patients with breast cancer.

March 28, 2012

For patients with metastatic colorectal cancer that has progressed on multiple lines of standard therapy, regorafenib may be a new treatment option that achieves disease control.